Vaccine Label Mix-Up Leads to Supreme Court Victory for Drug Regulators

In a significant ruling for criminal procedure in public servant-led prosecutions, the Supreme Court of India has held that magistrates are not required to conduct a mandatory inquiry under Section 202 CrPC before issuing summons to accused residing outside their territorial jurisdiction when the complaint is filed by a public servant like a Drugs Inspector. Justices Ahsanuddin Amanullah and S.V.N. Bhatti delivered the verdict in cross-appeals involving State of Kerala & Anr. v. M/s. Panacea Biotec Ltd. & Anr. , overturning Kerala High Court orders that quashed proceedings over procedural lapses.

The decision, cited as 2026 LiveLaw (SC) 206 , reinforces protections for official complaints while safeguarding consumer safety in drug misbranding cases.

From Clinic Complaint to Courtroom Drama

The saga began in 2005 when Mr. Joy Mandi alerted a Primary Health Centre in Thrissur, Kerala, about a labeling discrepancy in a vaccine purchased for his child. The outer carton claimed "Easy Five Pentavalent Vaccine" (including Hepatitis B component), but the inner vial read "Easy Four Tetravalent Vaccine" (lacking it). Priced differently and with mismatched batch details, the drug was flagged as misbranded under Sections 17(b), 17(c), and 18(a)(i) of the Drugs and Cosmetics Act, 1940 , read with Rule 96 of the Rules, 1945 , punishable under Section 27(d) .

The Drugs Inspector (Intelligence Branch), Thrissur, launched inquiries starting January 2006, seizing documents from sellers in the supply chain—ultimately tracing issues to manufacturer M/s. Panacea Biotec Ltd. (Delhi-based) and its then Managing Director. A formal complaint was filed in 2009 before the Chief Judicial Magistrate (CJM), Thrissur, after condoning delay under Section 473 CrPC .

Panacea challenged the 2012 summoning order under Section 482 CrPC , arguing no Section 202 CrPC inquiry due to their out-of-jurisdiction residence. The Kerala High Court agreed in 2022, quashing proceedings. Similar fate befell a related case against syringe makers Veekay Surgicals Pvt. Ltd. for substandard products.

Prosecutors' Stand: Public Servants Deserve Special Treatment

Kerala's counsel, Mr. H.V. Hameed, urged the apex court to recognize public servants' "different pedestal," citing Cheminova India Ltd. v. State of Punjab (2021) 8 SCC 818 . There, the Court exempted such complaints from rigorous pre-cognizance scrutiny to prevent harassment of innocents while trusting official probes. Delay was justified as identity emerged only after 2006 chain inspections (per Section 469(1)(c) CrPC ), ending April 18, 2006—well before the three-year limit under Section 468(2)(c) .

On vicarious liability under Section 34 of the Drugs Act , they invoked deeming provisions for company heads. The gravity of misbranding endangering public health, especially vaccines for children, demanded trial.

Defense Fires Back: No Exceptions, Procedure is King

Senior counsel Mr. Siddharth Luthra countered that the 2005 CrPC amendment made Section 202 inquiry "sine qua non" without public servant carve-outs. Unlike Cheminova , no Government Analyst Report corroborated claims—relying solely on a private individual's unverified labels. Bald vicarious liability averments failed Section 34 , and CJM's haste breached territorial safeguards.

Harmonizing the Code: Why Public Servants Get a Pass

The Bench dissected Sections 200 and 202 CrPC in tandem. Proviso to Section 200 skips examining public servant complainants acting officially, as here with the authorized Drugs Inspector under Section 32 of the Drugs Act . Insisting on Section 202 inquiry would undermine this, per Cheminova : legislatures placed public servants on a " different pedestal " to balance anti-harassment goals with enforcement efficiency.

On limitation, Section 469(1)(c) pinned commencement to offender identity revelation (April 2006), not initial knowledge (2005)—filing in 2009 cleared the bar. For syringes, director liability under Section 34 awaited trial facts.

The Court distinguished Birla Corporation Ltd. v. Adventz Investments (2019) 16 SCC 610 (private complainant) and cautioned: rulings fact-specific, no merits prejudice.

Key Observations Straight from the Bench

"The legislature in its wisdom has itself placed the public servant on a different pedestal, as would be evident from a perusal of proviso to Section 200 of the Code of Criminal Procedure." ( Cheminova quote adopted, Para 40)

"In this factual setting, Section 202 of the Code would necessarily have to be construed harmoniously with Section 200 of the Code when considering postponement of the issue of process." (Para 40)

"Whether or not, they were ‘in charge of’ and ‘responsible to the company for the conduct of the business of the company’ are questions of fact... best left to be determined by the Trial Court." (Para 59, on Section 34)

Summons Revived: A Green Light for Trials

All appeals allowed: High Court orders set aside, CJM proceedings restored with fresh summons. Deceased director replaced by relevant company heads. No costs.

This clarifies CrPC application in drug regulatory cases, easing prosecutions against distant pharma giants while prioritizing consumer protection. As LiveLaw notes, it aligns with BNSS Section 225 (CrPC successor), potentially streamlining public servant cases nationwide—vital amid rising substandard drug alerts.